Our results suggests that combining Aurora B and MPS1 inhibitors not only synergise in killing cancer cell lines, through synergistic override of the SAC, but more importantly, sensitise breast cancer cell lines to cell death that otherwise do not respond to Aurora B inhibitors alone. Here, AURKB is linked to breast carcinoma.